Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intra-Cellular Therapies Inc.

This article was originally published in Start Up

Executive Summary

Built on technology from the lab of Nobel laureate Paul Greengard, PhD, Intra-Cellular Therapies Inc. aims to develop small-molecule compounds that modify intracellular responses to endogenous neurotransmitters as therapeutics for Parkinson's disease, depression, schizophrenia and other CNS disorders.

You may also be interested in...



Biocortech

Biocortech was established in November 2001 to commercialize the fruits of the founders' research into the underlying causes of treatment-resistant forms of CNS diseases such as depression and schizophrenia. The company's aim is to develop effective therapies for these and other diseases associated with the pre-frontal cortex of the brain, such as bipolar disorder and cognitive and sexual disorders.

Functional Genetics Inc.

Functional Genetics has developed a method for simultaneously knocking out both alleles of a gene, even when that gene is not known. The technology enables the company to better associate gene with disease process and function up front in the drug discovery process.

Functional Genetics Inc.

Functional Genetics has developed a method for simultaneously knocking out both alleles of a gene, even when that gene is not known. The technology enables the company to better associate gene with disease process and function up front in the drug discovery process.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC090715

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel